# Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure

> **NCT00923156** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 123 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** aliskiren
- **DRUG:** ramipril
- **DRUG:** Placebo to aliskiren
- **DRUG:** Placebo to ramipril

## Key facts

- **NCT ID:** NCT00923156
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2012-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00923156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00923156, "Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00923156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*